How it works

As many as 40% of all pregnant women experience protracted labor, which carries a high risk of complications for both mothers and infants. Our own preclinical studies show for the first time that protracted labor and cervical ripening are related to a deficiency in heparan sulfate, a naturally occurring polysaccharide that plays an important role in labor and contributes to cervical softening.
Tafoxiparin, a proprietary heparan sulfate mimetic, has been shown in preclinical and clinical data to supplement and fulfill the role of heparan sulfate, which is a prerequisite for the optimal effectiveness of oxytocin. Tafoxiparins mechanism of action has been supported by preclinical experiments and in clinical studies when administered in combination with oxytocin as part of current clinical practices. Tafoxiparin can improve uterine contractions and may promote cervical softening, thereby demonstrating a potential to reduce the incidence of protracted labor and associated complications.

“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb